SHENZHEN, China, April 14, 2026 /PRNewswire/ -- Tencent Music Entertainment Group ("TME", or the "Company") (NYSE: TME and HKEX: 1698), the leading online music and audio entertainment platform in China, today announced that it will report its unaudited financial results for the first quarter of 2026 before the U.S. market opens on Tuesday, May 12, 2026.

TME's management will host a Tencent Meeting Webinar on Tuesday, May 12, 2026, at 7:00 A.M. Eastern Time or 7:00 P.M. Beijing/Hong Kong Time on Tuesday, May 12, 2026, to review and discuss the Company's business and financial performance.

For participants who wish to join the Tencent Meeting Webinar, please complete online registration in advance using the links provided below. Upon registration, each participant will receive an email with webinar access information, including meeting ID, meeting link, dial-in numbers, and a unique attendee ID to join the webinar.

Participant Online Registration

Chinese Mainland^[1]: https://meeting.tencent.com/dw/W1dA7Kx66kom
International:             https://voovmeeting.com/dw/W1dA7Kx66kom

A live and archived webcast of the webinar will also be available at the Company's investor relations website at https://ir.tencentmusic.com/.

^[1] Chinese Mainland, for the purpose of this announcement only, excluding the Hong Kong Special Administrative Region, the Macao Special Administrative Region of the People's Republic of China and Taiwan

About Tencent Music Entertainment

Tencent Music Entertainment Group (NYSE: TME and HKEX: 1698) is the leading online music and audio entertainment platform in China, operating the country's highly popular and innovative music apps: QQ Music, Kugou Music, Kuwo Music and WeSing. TME's mission is to create endless possibilities with music and technology. TME's platform comprises online music, online audio, online karaoke, music-centric live streaming and online concert services, enabling music fans to discover, listen, sing, watch, perform and socialize around music. For more information, please visit ir.tencentmusic.com.

Investor Relations Contact
Tencent Music Entertainment Group
[email protected]  
+86 (755) 8601-3388 ext. 885034

Goldman Sachs issued a research report saying that confidence is strengthening in sustained or accelerating AWS revenue growth of Amazon.com (AMZN.US), as well as stable margins.

Meanwhile, the broker believed that energy prices may have some impact on the Company's input costs and consumer demand, but it remains manageable within its forecasting framework.

Also, Goldman Sachs believed that the Company will benefit from a series of broader industry and budget allocation trends, which are favorable to its advertising segment.

Therefore, the broker chopped its target price from US$280 to US$275, with rating reiterated at Buy. Amazon.com remains one of the most attractive stocks in terms of medium- to long-term risk-reward among the shares under the broker's coverage.
~

AASTOCKS Financial News
Website: www.aastocks.com

美國馬里蘭州羅克維爾市和中國蘇州2026年4月14日 /美通社/ -- 致力於在腫瘤等領域開發創新藥物的領先的生物醫藥企業——亞盛醫藥（納斯達克代碼：AAPG；香港聯交所代碼：6855）宣佈，公司在研原創1類新藥、MDM2-p53 抑制劑APG- 115膠囊已被國家藥品監督管理局藥品審評中心（CDE）正式納入「兒童抗腫瘤藥物研發鼓勵試點計劃」（星光計劃）試點項目，擬開發用於治療神經母細胞瘤、橫紋肌肉瘤、尤文肉瘤等兒童實體瘤。這標誌著APG-115在兒童腫瘤領域的臨床開發進入加速通道，進一步完善了公司在該領域的戰略佈局。

「星光計劃」（SPARK計劃）是CDE專門為破解兒童抗腫瘤藥物研發難題而推出的重要試點，於2025 年 5 月 29 日正式啟動。該計劃旨在落實國家藥監局「提前介入、一企一策、全程指導、研審聯動」的要求，通過為創新藥提供全週期技術支持與審評加速，助力兒童抗腫瘤新藥高效研發與早日上市。

APG-115是亞盛醫藥自主研發的口服、高選擇性MDM2-p53 抑制劑，為首個在中國進入臨床階段的同類靶點品種和潛在的中國本土研發First-in-class新藥。該品種通過阻斷MDM2-p53相互作用，恢復p53的腫瘤抑制活性，從而誘導腫瘤細胞凋亡。依托公司在細胞凋亡領域的研發實力，APG-115此前已在多項成人臨床研究中展現出積極的抗腫瘤活性與安全性特徵，覆蓋血液腫瘤與多種實體瘤。

神經母細胞瘤、橫紋肌肉瘤和尤文肉瘤等兒童腫瘤，是一類對社會和家庭危害程度大的少發/罕見疾病，因治療難度大，長期存在極大的未被滿足的臨床需求。此前，亞盛醫藥已經開展了一項APG-115聯合利沙托克拉（商品名：利生妥^®；研發代號：APG-2575）治療復發或難治兒童神經母細胞瘤或實體腫瘤的I期臨床研究（APG115XC103）。此次APG-115獲納入「星光計劃」，將有助於公司與CDE的進一步緊密溝通，獲得兒童人群研究過程中技術問題的針對性指導。這將顯著加速APG-115在兒童實體瘤方向的臨床開發效率，使其盡早上市滿足患者需求，從而惠及更多兒童患者。

亞盛醫藥首席醫學官翟一帆博士表示：「兒童腫瘤尤其是罕見實體瘤長期面臨治療選擇有限、預後不佳的嚴峻挑戰。APG-115此次獲納入CDE『星光計劃』，是國家藥監機構對該品種臨床價值與研發前景的高度認可。公司將以此為契機，嚴格遵循『星光計劃』指導要求，高效推進兒童適應症臨床開發，力爭為中國及全球兒童腫瘤患者帶來安全、有效的創新治療方案，持續踐行'解決中國乃至全球患者尚未滿足的臨床需求'的企業使命。」

關於亞盛醫藥

亞盛醫藥（納斯達克代碼：AAPG；香港聯交所代碼：6855）是一家綜合性的全球生物醫藥企業，致力於研發、生產和商業化創新藥，以解決腫瘤領域全球患者尚未滿足的臨床需求。公司已建立豐富的創新藥產品管線，包括抑制Bcl-2和 MDM2-p53 等細胞凋亡通路關鍵蛋白的抑制劑、新一代針對癌症治療中出現的激酶突變體的抑制劑以及蛋白降解劑。

公司核心品種耐立克^®是中國首個獲批上市的第三代BCR-ABL抑制劑，已獲批用於治療伴有T315I突變的慢性髓細胞白血病慢性期（CML-CP）和加速期（CML-AP）患者，以及對一代和二代TKI耐藥和/或不耐受的CML-CP成年患者。該藥物所有獲批適應症均已被納入中國國家醫保藥品目錄（NRDL）。目前，亞盛醫藥正在開展耐立克^®三項全球註冊III期臨床研究，分別為：獲美國FDA和歐洲EMA許可的評估耐立克^®治療新診斷費城染色體陽性急性淋巴細胞白血病（Ph+ ALL）患者POLARIS-1研究；獲美國FDA和歐洲EMA許可的評估耐立克^®治療經治CML-CP成年患者的POLARIS-2研究；評估耐立克^®治療SDH-缺陷型GIST患者的POLARIS-3研究。

公司另一重磅品種利生妥^®是一款用於治療多種血液系統惡性腫瘤的新型Bcl-2抑制劑。利生妥^®已獲中國國家藥品監督管理局（NMPA）批准，用於治療既往至少接受過一種包括布魯頓酪氨酸激酶（BTK）抑制劑在內的系統治療的成人慢性淋巴細胞白血病/小淋巴細胞淋巴瘤（CLL/SLL）患者。目前，亞盛醫藥正在開展利生妥^®四項全球註冊III期臨床研究，分別為：獲美國FDA和歐洲MEA許可的評估利生妥^®聯合BTK抑制劑治療既往接受BTK抑制劑治療超過12個月且應答不佳的CLL/SLL患者的GLORA研究；評估利生妥^®一線治療初治CLL/SLL患者的GLORA-2研究；評估利生妥^®一線治療新診斷老年或不耐受的AML患者的GLORA-3研究；以及獲美國FDA和歐洲EMA許可的評估利生妥^®一線治療新診斷中高危MDS患者的GLORA-4研究。

憑借強大的研發能力，亞盛醫藥已在全球範圍內進行知識產權佈局，並與武田、阿斯利康、默沙東、輝瑞、信達等眾多領先的生物製藥公司達成全球合作，同時與丹娜法伯癌症研究院、梅奧醫學中心、美國國家癌症研究所和密西根大學等學術機構建立研發合作關係。如需瞭解更多信息，請訪問 https://ascentage.com/

前瞻性聲明

本新聞稿包含根據美國《1995年私人證券訴訟改革法案》，以及經修訂的《1933年證券法》第27A條和《1934年證券交易法》第21E條所界定的前瞻性陳述。除歷史事實陳述外，本新聞稿中的所有內容均可能構成前瞻性陳述，包括亞盛醫藥對未來事件、經營成果或財務狀況所發表的意見、預期、信念、計劃、目標、假設或預測。

這些前瞻性陳述受到諸多風險和不確定性的影響，具體內容已在亞盛醫藥向美國證券交易委員會（SEC）提交的文件中詳細說明，包括2025年1月21日提交的經修訂的F-1表格註冊說明書和2025年4月16日提交的20-F表格中的「風險因素」和「關於前瞻性聲明的警示聲明」章節、2019年10月16日提交的首次發行上市招股書中的「前瞻性聲明」、「風險因素」章節，以及我們不時向SEC或HKEX提交的其他文件。這些因素可能導致實際業績、運營水平、經營成果或成就與前瞻性陳述中明示或暗示的信息存在重大差異。本前瞻性聲明中的陳述不構成公司管理層的利潤預測。

因此，該等前瞻性陳述不應被視為對未來事件的預測。本新聞稿中的前瞻性陳述僅基於亞盛醫藥當前對未來發展及其潛在影響的預期和判斷，且僅代表截至陳述發表之日的觀點。無論出現新信息、未來事件或其他情況，亞盛醫藥均無義務更新或修訂任何前瞻性陳述。

HONG KONG, April 14, 2026 /PRNewswire/ -- KLN Logistics Group Limited ('KLN'; Stock Code 0636.HK) today announced three strategic executive appointments aimed at accelerating its global expansion and strengthening its financial resilience, workforce transformation and long-term sustainable growth.

Davis Cho has been appointed Chief Financial Officer of KLN, effective 1 April 2026, and will be appointed Executive Director, effective 21 May 2026. He brings over 25 years of experience in accounting, finance and internal controls, with deep expertise in financial governance and strategic oversight. Prior to joining KLN, he was a partner in the Assurance division at PricewaterhouseCoopers from 2011 to 2026. In his new role, Davis will work closely with the Board in enhancing KLN's financial discipline and supporting its global growth strategy.

Helena Shen joined KLN as Chief Human Resources Officer on 23 February 2026. She brings extensive international experience across Asia and Europe and has held senior HR leadership roles at multinational corporations. With a strong track record in workforce transformation, mergers and acquisitions integration, and employee engagement, she will help shape KLN's culture and align its talent strategy and HR operating model with the company's long-term business goals.

Wong Siew Loong, Chief Operating Officer of KLN, will be appointed Executive Director with effect from 21 May 2026. In his leadership role, he oversees the company's global operations, driving operational integration and service excellence across markets. Since joining KLN, he has played a pivotal role in enhancing growth, efficiency and scalability, and in leading the KLN 2.0 transformation across the network. With over 25 years of experience in the global transportation and logistics industry, he brings a strong track record of leadership and innovation to the Board.

Commenting on the appointments, Vic Cheung, Executive Director and CEO of KLN, said, "These appointments underscore our commitment to building a resilient and forward-looking organisation. Siew Loong, Davis and Helena bring complementary strengths that will be instrumental in advancing our transformation journey as we continue to build a global supply chain powerhouse.

He added, "On behalf of the Management Team, I would also like to express our sincere gratitude to Ellis Cheng, our outgoing CFO and Executive Director, for strengthening the company's financial foundation and driving growth during his tenure. We are pleased that he will continue to support KLN as an advisor, and we wish him all the best in his retirement."

-End-

About KLN Logistics Group Limited (Stock Code 0636.HK)

KLN is an Asia-based, global 3PL with a highly diversified business portfolio and extensive coverage in Asia. It offers a broad range of supply chain solutions from integrated logistics, international freight forwarding (air, ocean, road, rail and multimodal) and e-commerce to industrial project logistics and infrastructure investment.

With a global presence across 58 countries and territories, KLN has established a solid foothold in half of the world's emerging markets. Its diverse infrastructure, extensive coverage in international gateways and local expertise span across the Chinese Mainland, India, Southeast Asia, the CIS, Middle East, LATAM and other locations.

KLN generated a revenue* of over HK$56 billion in 2025. It is listed on the Hong Kong Stock Exchange and is a constituent of the Hang Seng Corporate Sustainability Benchmark Index.

香港2026年4月14日 /美通社/ -- KLN Logistics Group Limited（「KLN」；股份代號0636.HK）今天公佈三項策略性高層管理人員的任命，旨在加速公司環球業務擴展，並強化其財務韌性、人才轉型及長期可持續增長。

曹健麟於2026年4月1日獲委任為KLN首席財務主管，並將於2026年5月21日起獲委任為執行董事。他於會計、財務及內部監控方面擁有逾25年經驗，並在財務管治與策略監督方面具備深厚專業知識。在加入KLN之前，曹健麟於2011年至2026年期間為羅兵咸永道會計師事務所審計業務部合夥人。在新職務上，他將與董事會緊密合作，提升KLN的財務紀律及支持其環球增長策略方面發揮關鍵作用。

沈暉於2026年2月23日加入KLN，擔任首席人力資源主管，她擁有橫跨亞洲與歐洲的豐富國際經驗，並曾在多家跨國企業擔任資深人力資源管理職務。憑藉在人才轉型、併購整合及員工投入度方面的卓越往績，沈暉將協助塑造KLN的企業文化，令其人才與人力資源營運模式與長期業務目標保持一致。

KLN首席營運主管黃兆龍將於2026年5月21日起獲委任為執行董事。在其領導職位上，他將負責監督環球營運，推動各市場的營運整合與卓越服務。自加入KLN以來，黃兆龍在推動公司增長、提升效率及擴展能力方面扮演關鍵角色，並領導KLN 2.0計劃在整個網絡的推行。憑藉逾25年環球運輸及物流行業的豐富經驗，他將為董事會帶來卓越的領導力與創新實績。

就相關任命，KLN執行董事及行政總裁張炳銓表示：「上述任命體現我們致力打造具韌性及前瞻視野的公司。黃兆龍、曹健麟與沈暉具備的互補優勢，將在我們推動策略轉型、邁向環球供應鏈領導者的過程中發揮關鍵作用。」

他補充說：「本人謹代表管理團隊，向即將卸任的首席財務主管兼執行董事鄭志偉致以誠摯謝意，感謝他在任內鞏固公司的財務基礎，並推動業務持續增長。我們欣悉他將繼續以顧問身份支持KLN，並祝願他退休生活一切順遂。」

-完-

關於KLN Logistics Group Limited（股份代號0636.HK）

KLN是以亞洲為基地，擁有高度多元化業務及強大亞洲網絡覆蓋的國際第三方物流服務供應商，業務涵蓋一系列供應鏈解決方案，包括綜合物流、國際貨運（海陸空、鐵路及多式聯運）及電子商貿，以及工業項目物流和基建投資等。

KLN的辦事處遍佈全球58個國家及地區，於全球一半新興市場設立據點，其多元基建設施、廣泛國際樞紐覆蓋和本地專業知識遍及中國內地、印度、東南亞、獨聯體、中東、拉美及其他地區。

KLN於2025 年全年收入*逾560億港元，於香港聯合交易所上市，並是恒生可持續發展企業基準指數成份股。

* 僅就持續經營業務而言

UBS published a research report on Intel (INTC.US), which saw resilient PC demand, with server CPU demand also swelling. The company raised prices by about 10%, and further price increases were expected within the year, particularly in the enterprise server.

The broker slightly raised its 1Q revenue forecast for the group from the previous USD12.2 billion to USD12.5 billion, while maintaining its EPS forecast at USD0.06. For 2026-28, revenue forecasts were lifted from USD51.1 billion, USD52.4 billion and USD56.1 billion to USD53.1 billion, USD55.1 billion and USD58.5 billion, respectively. EPS forecasts were also revised up from USD0.35, USD0.6 and USD0.92 to USD0.44, USD0.75 and USD1.05, respectively.

UBS noted that Intel's foundry business outlook is improving, particularly in relation to its 14A process technology. It expected customers including Google, Apple (AAPL.US), AMD (AMD.US) and NVIDIA (NVDA.US) to sign foundry commitments this fall. In addition, the potential scenario of merging the Ohio wafer fab project with Elon Musk's TeraFab adds confidence to the long-term prospects of the foundry business.

UBS maintained a Neutral rating on Intel, raising its TP from USD51 to USD65.
~



AASTOCKS Financial News
Website: www.aastocks.com

SINGAPORE, April 14, 2026 /PRNewswire/ -- Midea Building Technologies (MBT), a business unit of Midea Group, together with Keppel Ltd.'s Infrastructure Division (Keppel), has entered into a strategic collaboration agreement to jointly develop AI-enabled, energy-efficient cooling solutions across Asia. The signing was witnessed by Ms Cindy Lim, CEO of Keppel's Infrastructure Division and Mr Peter Guan, Vice President of Midea Group and President of MBT.

The non-exclusive collaboration will combine MBT's capabilities in heating, ventilation, and air conditioning manufacturing and intelligent building systems with Keppel's strengths in Cooling-as-a-Service (CaaS) and digital optimisation, to co-develop standardised, modular cooling systems. Implementation of the modular cooling system in specific projects will be carried out through project agreements separately negotiated by Keppel and MBT on a case-by-case basis.  

It is envisaged that the jointly developed modular cooling systems will offer a flexible, capex-light solution that can be deployed and scaled across multiple sectors, which will enhance the energy efficiencies of cooling processes while reducing the complexity of on-site installation.

By adopting a modular, pre-engineered approach, Keppel can pre-fabricate cooling modules and assemble them onsite. The modular cooling systems will be connected to Keppel's state-of-the-art Operations Nerve Centre (ONC). The ONC, in turn, runs on Keppel's proprietary digital platform, Infrastructure Intelligence (II), which leverages AI and machine learning for real-time monitoring and performance advanced analytics, allowing the cooling modules to be managed remotely around the clock.

When combined with MBT's smart equipment, IoT sensors and intelligent building management systems, it is expected that the AI-enabled cooling solution will be able to offer enhanced operational reliability, improved energy efficiency and reduced lifecycle carbon emissions generated from cooling processes.

As part of the collaboration, both companies will establish an AI-first Centre of Excellence, a collaborative platform, to facilitate engineering, standardisation, optimisation and replication across potential projects. Target sectors include data centres, advanced manufacturing and industrial parks, healthcare and education campuses, aviation hubs, integrated developments and retrofit projects.

Mr Peter Guan, Vice President of Midea Group and President of MBT, said: "This partnership unlocks the full potential of industrialised AI for cooling. MBT brings scalable manufacturing, equipment-level intelligence, and proven modular architectures that can be rapidly replicated across cities and sectors. Together with Keppel's operational platforms, we are moving from one-off projects to repeatable, standardised solutions – making sustainable cooling accessible and affordable at scale."

Mr Poh Tiong Keng, Executive Director, Energy-as-a-Service, Keppel, said, "This collaboration further strengthens our ability to develop and deploy next-generation cooling solutions across Asia. By combining Keppel's Operations Nerve Centre and deep operating capabilities with Midea's engineering and manufacturing strengths, we are helping to accelerate the adoption of intelligent, AI-enabled infrastructure at scale across multiple sectors. We look forward to building on Keppel's ongoing collaboration with Midea, which includes Keppel's HDB Tengah Centralised Cooling Systems project in Singapore."

About Midea

Midea Group Co., Ltd. (000333.SZ, 00300.HK) is an international tech-leading company ranked #246 at 2025's Fortune Global 500. Midea Group's business comprises smart home, industrial technology, building technology, robotics and automation, new energy, healthcare, and smart logistics. Midea's globally 65 production centers and over 190,000 employees in more than 200 countries and regions generated an annual revenue of more than USD 64.3 billion in 2025. Midea's 41 worldwide innovation centers and the strong commitment to R&D have resulted in more than 90,000 authorized patents to-date.

About Keppel

Keppel Ltd. (SGX:BN4) is a global asset manager and operator with strong expertise in sustainability-related solutions spanning the areas of infrastructure, real estate and connectivity. Headquartered in Singapore, Keppel operates in more than 20 countries worldwide, providing critical infrastructure and services for renewables, clean energy, decarbonisation, sustainable urban renewal and digital connectivity. Keppel creates value for investors and stakeholders through its quality investment platforms and diverse asset portfolios, including private funds and listed real estate and business trusts.

Meta Platforms (META.US) is developing an AI version of Chief Executive Mark Zuckerberg to engage with employees in his stead, the Financial Times quoted sources as saying.

Zuckerberg is personally involved in training and testing his AI avatar, which will in future be able to offer conversation and feedback to employees, sources noted. The avatar is being trained to mimic Zuckerberg's mannerisms, tone and public remarks, while incorporating his recent thinking on the Company's strategies.
~

AASTOCKS Financial News
Website: www.aastocks.com

Apple (AAPL.US) is expected to enter the foldable smartphone market as early as 2H26, according to display industry research by market research firm TrendForce.

Leveraging its strong brand positioning and consumer anticipation, Apple is projected to capture nearly 20% market share this year, compressing the market shares of Samsung Electronics and Huawei to around 30% each.

Efforts to reduce screen creases are shifting from traditional mechanical solutions reliant on hinges and support structures to material-oriented approaches focused on managing structural stress, TrendForce added.
~

AASTOCKS Financial News
Website: www.aastocks.com

CHENGDU, China, April 14, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that results from both the ovarian cancer cohort and the cervical cancer cohort of Phase II study SKB264-II-06/MK-2870-002 of the TROP2 ADC sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870) (佳泰莱^®), in combination with MSD's^[1] anti-PD-1 monoclonal antibody pembrolizumab (KEYTRUDA^®[2]), were selected for oral presentation at the 2026 Society of Gynecologic Oncology (SGO) Annual Meeting in San Juan, Puerto Rico. The data were presented by Professor Xiaohua Wu of Fudan University Shanghai Cancer Center.

Ovarian cancer

This presentation reported, for the first time, important data on sac-TMT as maintenance treatment in breast cancer susceptibility gene (BRCA) wild-type, second-line platinum-sensitive recurrent ovarian cancer. Among the 40 patients enrolled in the ovarian cancer cohort, 27 received sac-TMT (4 mg/kg, every other week (Q2W)) in combination with pembrolizumab, and 13 received sac-TMT (5 mg/kg, Q2W) in combination with pembrolizumab. Among the enrolled patients, 70% had prior bevacizumab therapy, and 58% had prior PARP inhibitor therapy. The median follow-up was 22.2 months (data cutoff date: November 17, 2025).

The data showed that median progression-free survival (PFS) in the overall population was 20.9 months; median overall survival (OS) was not reached; and the 12-month OS rate was 92%. Additionally, the adverse events of sac-TMT in combination with pembrolizumab were manageable. The most common treatment-related adverse events (TRAEs) were anemia, stomatitis, and decreased neutrophil count. No deaths or discontinuations due to sac-TMT-related TRAEs was reported.

The study results showed that sac-TMT in combination with pembrolizumab as maintenance therapy for platinum-sensitive recurrent ovarian cancer demonstrated positive efficacy signals and a favorable safety profile, providing important evidence for further clinical exploration of this combination regimen in the ovarian cancer population.

Cervical cancer

A total of 68 patients with previously treated second-line or third-line recurrent or metastatic cervical cancer were enrolled in the cervical cancer cohort to receive sac-TMT at doses of 3 mg/kg, 4 mg/kg, or 5 mg/kg Q2W in combination with pembrolizumab. Among the enrolled patients, 57% had prior bevacizumab therapy, and 51% had prior immunotherapy. The median follow-up was 24.7 months (data cutoff date: November 17, 2025).

The data showed that after treatment with sac-TMT in combination with pembrolizumab, the objective response rate (ORR) in the total population was 51% and 54% in IO-pretreated population. The median PFS was 7.3 months and the median OS reached 18.9 months in the total population. Furthermore, the safety profile of sac-TMT in combination with pembrolizumab was manageable, with no new safety signals identified and no deaths due to TRAEs.

The study results demonstrated promising and durable antitumor activity with a manageable safety profile in patients with pre-treated second-line or third-line recurrent or metastatic cervical cancer receiving sac-TMT in combination with pembrolizumab, providing robust data to support further clinical development.

About sac-TMT

Sac-TMT, a core product of the Company, is a novel human TROP2 ADC in which the Company has proprietary intellectual property rights, targeting advanced solid tumors such as NSCLC, breast cancer (BC), gastric cancer (GC), gynecological tumors and genitourinary tumors, among others. Sac-TMT is developed with a unique, bifunctional linker that maximizes payload delivery to tumor cells both through its irreversible connection with the anti-TROP2 monoclonal antibody sacituzumab and its pH-sensitive cleavage from a belotecan-derivative topoisomerase I inhibitor in the lysosome, with a drug-to-antibody-ratio (DAR) of 7.4. Sac-TMT specifically recognizes TROP2 on the surface of tumor cells by recombinant anti-TROP2 humanized monoclonal antibodies, which is then endocytosed by tumor cells and releases the payload KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment. Given that KL610023 is membrane permeable, it can enable a bystander effect, or in other words kill adjacent tumor cells.

In May 2022, the Company licensed the exclusive rights to MSD (the tradename of Merck & Co., Inc, Rahway, NJ, USA) to develop, use, manufacture and commercialize sac-TMT in all territories outside of Greater China (which includes Mainland China, Hong Kong, Macao and Taiwan).

To date, four indications for sac-TMT have been approved and marketed in China for: EGFR mutant-positive locally advanced or metastatic non-squamous NSCLC following progression on EGFR-TKI therapy and platinum-based chemotherapy; unresectable locally advanced or metastatic TNBC who have received at least two prior systemic therapies (at least one of them for advanced or metastatic setting); EGFR mutant-positive locally advanced or metastatic non-squamous NSCLC who progressed after treatment with EGFR-TKI therapy; unresectable or metastatic HR+/HER2- (IHC 0, IHC 1+ or IHC 2+/ISH-) BC who have received prior ET and at least one line of chemotherapy in advanced setting. The first two indications listed above have been included in China's National Reimbursement Drug List (NRDL). This inclusion is expected to bring clinical benefits to a greater number of patients with BC and NSCLC. Additionally, sac-TMT has been granted six Breakthrough Therapy Designations (BTDs) by the NMPA.

Sac-TMT is the world's first TROP2 ADC drug approved for marketing in lung cancer. As of today, Kelun-Biotech has initiated 9 registrational clinical studies in China. MSD is evaluating 17 ongoing Phase III global clinical studies of sac-TMT as a monotherapy or with pembrolizumab or other anti-cancer agents for several types of cancer. These studies are sponsored and led by MSD.

About Kelun-Biotech

Kelun-Biotech (6990.HK) is a holding subsidiary of Kelun Pharmaceutical, which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. Kelun-Biotech focuses on major disease areas such as solid tumors, autoimmune, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. Kelun-Biotech is committed to becoming a leading global enterprise in the field of innovative drugs. At present, Kelun-Biotech has more than 30 ongoing key innovative drug projects, of which 4 projects with 8 indications have been approved for marketing, more than 10 projects are in the clinical stage. Kelun-Biotech has established one of the world's leading proprietary ADC and novel DC platforms, OptiDC™, and has 2 ADC projects with 5 indications approved for marketing, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit https://en.kelun-biotech.com/.